Investors & Media

Omega Therapeutics is a development-stage biotechnology company leveraging it OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines. With its computation- and data-first approach, Omega Therapeutics is advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.